

Delivering Consistently for Our Shareholders

Dechra is a company that has consistently delivered on its strategic objectives resulting in a strong track record of growth.



Period	Underlying Profit Before Taxation	Market Capitalisation	Key Events
1 July 1996 to 30 June 1997	£0.1m		
1 July 1997 to 30 June 1998	£0.7m		
1 July 1998 to 30 June 1999	£2.1m		
1 July 1999 to 30 June 2000	£5.8m	£88.9m	June 1997 Management buyout from Lloyds Chemist plc supported by Mercury and Bank of Scotland.
1 July 2000 to 30 June 2001	£7.5m	£62.0m	September 2000 Dechra listed on the London Stock Exchange at 120 pence per share, with a market capitalisation of £60.0 million.
1 July 2001 to 30 June 2002	£6.7m	£44.6m	December 2001 Vetoryl® launched in the UK. April 2002 Acquired North Western Laboratories and Cambridge Specialist Laboratory Services for a consideration of £2.75 million, enabling Dechra to extend its service offering to the veterinary profession. April 2002 Felimazole® launched in the UK. May 2002 Acquired Anglian Pharma Plc for a consideration of £2.5 million which more than doubled Dechra's contract manufacturing revenues.
1 July 2002 to 30 June 2003	£8.1m	£76.2m	April 2003 North Western Laboratories rebranded to NationWide Laboratories. May 2003 Entered into a sub-licence agreement with Bioevision Inc. to develop Vetoryl for future marketing in the US and Canada.
1 July 2003 to 30 June 2004	£9.7m	£108.1m	December 2003 Entered into a European marketing agreement with Janssen Animal Health, allowing Janssen full marketing and distribution rights to Felimazole and Vetoryl in mainland Europe. April 2005 Opened a US operation based in Kansas City.
1 July 2004 to 30 June 2005	£11.0m	£124.6m	November 2004 Granted a full EU licence for Felimazole and granted a UK licence for a new 2.5mg Felimazole tablet. April 2005 Granted a range extension for a 30mg Vetoryl capsule. April 2005 Acquired VetVex®, a licensed veterinary fluid therapy product for £0.8 million.
1 July 2005 to 30 June 2006	£12.7m	£183.7m	July 2005 Received approval to market Vetoryl in 19 major European countries. June 2006 Signed a development and marketing agreement for Vetoryl in Japan with Kyoritsu Seiyaku. December 2006 Acquired the intellectual property for Equidone® Gel. April 2007 Acquired Leeds Veterinary Laboratories for £0.75 million. May 2007 Secured a long term trademark licence and marketing agreement with Pharmaderm Animal Health for a consideration of US\$5.0 million, to supply a range of dermatological, ophthalmic and optic products to the US veterinary market.
1 July 2006 to 30 June 2007	£16.9m	£274.0m	January 2008 Acquired VetXX Holding A/S, a leading developer, producer and marketer of companion animal products, for a total consideration of £61.7 million.
1 July 2007 to 30 June 2008	£23.4m	£276.9m	December 2008 VetXX integrated and rebranded Dechra Veterinary Products. December 2008 Received FDA approval for Vetoryl in the USA. May 2009 New therapeutic canine diet developed and marketed to aid treatment of osteoarthritis in dogs, known as Specific®.
1 July 2008 to 30 June 2009	£26.1m	£254.4m	November 2009 Achieved mutual recognition of Malaseb® in 17 European countries. February 2010 DVP UK's logistics and finance function integrated into an European central logistic and shared service centre in Ulkum, Denmark.
1 July 2009 to 30 June 2010	£30.1m	£326.1m	October 2010 Acquired DermaPet® Inc., a Florida based dermatological business, for a total consideration of US\$64.0 million. The acquisition strengthened Dechra's position as a leader in the worldwide veterinary dermatological market. December 2010 Acquired Genitrix Limited, a privately owned veterinary company with a range of products complementary to Dechra's, for a total consideration of £8.4 million.
1 July 2010 to 30 June 2011	£33.0m	£422.1m	January 2012 Acquired the worldwide rights (excluding Canada) to HY-50® for a cash consideration of CAD 8.03 million. May 2012 Acquired Eurovet® Animal Health B.V., an expert in developing, registering, producing and marketing added value, companion and farm animal veterinary pharmaceutical products, for a total cash consideration of €135 million.
1 July 2011 to 30 June 2012	£44.6m	£601.3m	May 2013 Skipton and Bladel sites renamed Dechra Manufacturing. Announced the closure of our manufacturing site in Ulkum, Denmark. March 2014 Commenced trading in Italy. May 2014 Acquired business and assets of PSPC, Inc. for a consideration of up to US\$10 million.
1 July 2012 to 30 June 2013	£39.8m	£634.6m	August 2013 Divested Services Segment to Patterson Companies, Inc. for £87.5 million, creating a pure veterinary pharmaceuticals and related products business. March 2014 Commenced trading in Italy. May 2014 Acquired business and assets of PSPC, Inc. for a consideration of up to US\$10 million.
1 July 2013 to 30 June 2014	£45.1m	£864.7m	January 2015 Commenced trading in Canada. May 2015 Commenced trading in Poland.
1 July 2014 to 30 June 2015	£49.7m	£1,087.0m	October 2015 Acquired 92.65% controlling interest in Genera® d.d., the oldest and largest manufacturer of animal health products in Croatia, for a total consideration of £26.8 million. January 2016 Acquired 100% of Laboratorios Brovel S.A. de C.V., a family owned veterinary pharmaceutical company located in Mexico City, Mexico, for a consideration of £3.3 million and a further £3.6 million contingent upon reaching registrations milestones. January 2016 Commenced trading in Austria. April 2016 Acquired Putney®, Inc., a leading developer of FDA approved CAP in the US, for a consideration of £134.2 million.
1 July 2015 to 30 June 2016	£77.0m	£1,584.0m	October 2016 Acquired business and assets of Apex Laboratories Pty Ltd, a veterinary pharmaceutical company which manufactures, markets and sells branded prescription products for companion animals in Australia and New Zealand for a total consideration of AUD\$55.0 million (£34.2 million). March 2017 Entered a long term Intellectual Property Licensing Agreement with Animal Ethics Pty Ltd to sell and market Tri-Solter® for all animal species in all international markets, excluding Australia and New Zealand. Acquired 33.0% of the issued share capital of Medical Ethics Pty Ltd (Medical Ethics), the parent company of Animal Ethics, for a total consideration of AUD\$18.0 million (£11.0 million).

Our History

The Company was incorporated in May 1997 to effect the management buyout from Lloyds Chemist plc. Three years later, in 2000, the issued ordinary share capital of Dechra was listed on the London Stock Exchange. Since 2000, the Company has grown strongly through a combination of innovation, organic growth and acquisition.

Underlying Profit Before Taxation is defined as operating profit excluding amortisation of acquired intangibles and impairment of acquired intangibles, impairment of investments, acquisition expenses, fair value uplift of inventory acquired through business combinations, rationalisation costs, loss on extinguishment of debt, and fair value and other movements on deferred and contingent consideration

Continuing Our Growth Story

- Clear Strategic Focus
- Development Pipeline
- Entrepreneurial and Innovative
- Manufacturing Flexibility
- Growing Animal Health Market
- Focused Portfolio
- Recognised Brand
- Expanding International Focus
- Talented People and Expertise
- Strong Balance Sheet

† Adjusted for the bonus element of the Rights Issue.